EAST RUTHERFORD, N.J.
Jan. 6, 2011
/PRNewswire/ -- Cambrex Corporation (NYSE: CBM) announced today that Cambrex Zenara is supplying product for Johnson & Johnson Limited's launch of Nicorette®, a leading smoking cessation product, in
. The Nicorette® product is being manufactured and packaged by Cambrex Zenara in its
"Nicotine Replacement Therapeutics represent an important part of our product portfolio," commented
Steven M. Klosk
, President and CEO of Cambrex. "It is estimated that
has over 270 million tobacco users, second only to
, and we are proud to supply product for Johnson & Johnson's launch of Nicorette® in this market."
, President of Cambrex Zenara said, "Being selected by Johnson & Johnson as their manufacturing partner is a testament to Cambrex Zenara's ability to supply product for a well-known brand to a very large market. This demonstrates our commitment to provide high quality, affordable solutions for smoking cessation."
About Cambrex Zenara
Cambrex Zenara develops and manufactures NRT products and provides high quality and competitively priced pharmaceutical drug product, formulation, development and manufacturing capabilities designed to accelerate commercialization of finished dosage forms for the pharmaceutical industry.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. We offer Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit
SOURCE Cambrex Corporation